Ugo De Giorgi Selected Research

Biomarkers (Surrogate Marker)

1/2022	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
1/2022	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.
1/2022	Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer.
10/2021	Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications.
10/2021	Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer.
1/2021	Spotlight on PSMA as a new theranostic biomarker for bladder cancer.
1/2021	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
1/2021	Talazoparib: a new biomarker-directed therapy in advanced prostate cancer.
12/2020	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
10/2020	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ugo De Giorgi Research Topics

Disease

93	Prostatic Neoplasms (Prostate Cancer) 07/2022 - 10/2012
82	Neoplasms (Cancer) 10/2022 - 01/2002
66	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 08/2013
38	Neoplasm Metastasis (Metastasis) 07/2022 - 09/2005
22	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2022 - 01/2002
20	Carcinoma (Carcinomatosis) 01/2022 - 01/2017
14	Disease Progression 01/2022 - 12/2018
14	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2002
11	Ovarian Neoplasms (Ovarian Cancer) 10/2021 - 05/2014
10	Urinary Bladder Neoplasms (Bladder Cancer) 02/2022 - 08/2016
7	Seminoma 10/2021 - 02/2005
7	Fatigue 01/2020 - 08/2013
6	Circulating Neoplastic Cells 01/2022 - 07/2009
6	Inflammation (Inflammations) 01/2021 - 01/2016
6	Human Influenza (Influenza) 01/2021 - 10/2018
5	Kidney Neoplasms (Kidney Cancer) 10/2022 - 01/2016
5	Pain (Aches) 01/2022 - 03/2015
5	Testicular Neoplasms (Testicular Cancer) 01/2022 - 02/2005
5	Neutropenia 12/2020 - 06/2003
5	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 10/2012 - 03/2005
4	Diarrhea 01/2021 - 04/2014
4	Hypertension (High Blood Pressure) 01/2021 - 03/2014
3	Ovarian Epithelial Carcinoma 01/2021 - 12/2018
3	Pneumonia (Pneumonitis) 12/2020 - 07/2006
3	Autoimmune Diseases (Autoimmune Disease) 06/2020 - 01/2019
3	Urologic Neoplasms (Urological Cancer) 10/2019 - 01/2019
3	Stomatitis 01/2017 - 03/2015
3	Lymphopenia (Lymphocytopenia) 12/2015 - 08/2012

Drug/Important Bio-Agent (IBA)

31	enzalutamideIBA 04/2022 - 12/2014
26	abirateroneIBA 04/2022 - 06/2014
25	PlatinumIBA 02/2022 - 12/2016
24	Immune Checkpoint InhibitorsIBA 10/2022 - 04/2018
22	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
20	Sunitinib (Sutent)FDA Link 02/2022 - 08/2013
20	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 11/2015
17	Docetaxel (Taxotere)FDA Link 01/2022 - 06/2014
16	cabozantinibIBA 10/2022 - 01/2016
16	NivolumabIBA 10/2022 - 09/2016
15	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 01/2015
15	pazopanib FDA Link 01/2022 - 08/2013
14	AndrogensIBA 03/2022 - 10/2012
14	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 01/2003
12	Bevacizumab (Avastin)FDA Link 02/2022 - 06/2011
12	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 06/2015
11	Biological ProductsIBA 01/2021 - 10/2016
9	Everolimus FDA Link 01/2022 - 10/2016
9	Hormones (Hormone)IBA 12/2021 - 03/2012
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 10/2004
7	Pharmaceutical PreparationsIBA 07/2022 - 01/2015
7	Tyrosine Kinase InhibitorsIBA 02/2022 - 01/2015
6	atezolizumabIBA 02/2022 - 01/2018
6	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 06/2015
6	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 03/2014
6	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2015
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 03/2014
5	cabazitaxel FDA Link 01/2022 - 07/2015
5	AntigensIBA 01/2021 - 12/2017
5	CytokinesIBA 01/2019 - 01/2016
5	Imatinib Mesylate (Gleevec)FDA Link 10/2012 - 03/2005
4	LigandsIBA 02/2022 - 10/2016
4	Hemoglobins (Hemoglobin)IBA 01/2022 - 04/2015
4	infigratinibIBA 01/2022 - 01/2018
4	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 04/2016
4	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2021 - 10/2018
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2015
4	Abiraterone AcetateIBA 12/2016 - 05/2015
4	human ERBB2 proteinIBA 03/2016 - 06/2011
3	IpilimumabIBA 10/2022 - 01/2022
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2022 - 01/2019
3	Angiogenesis InhibitorsIBA 12/2021 - 05/2014
3	B7-H1 AntigenIBA 11/2021 - 01/2019
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 07/2021 - 12/2016
3	Chimeric Antigen ReceptorsIBA 02/2021 - 10/2019
3	Gemcitabine FDA Link 01/2021 - 10/2004
3	gallium 68 PSMA-11IBA 11/2020 - 11/2018
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2020 - 12/2016
3	Estrogen ReceptorsIBA 08/2020 - 08/2012
3	Taxoids (Taxanes)IBA 01/2020 - 01/2018
3	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 01/2020 - 02/2016
3	taxaneIBA 01/2019 - 03/2015
3	Axitinib (AG 013736)IBA 01/2019 - 01/2016
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2018 - 10/2004
3	Chromogranin AIBA 10/2018 - 06/2014
2	darolutamideIBA 03/2022 - 05/2021
2	Androgen Antagonists (Antiandrogens)IBA 03/2022 - 01/2019
2	Trastuzumab (Herceptin)FDA Link 01/2022 - 06/2011

Therapy/Procedure

84	Therapeutics 10/2022 - 06/2003
73	Castration 07/2022 - 10/2012
62	Drug Therapy (Chemotherapy) 02/2022 - 01/2002
15	Immunotherapy 01/2022 - 08/2016
9	Radiotherapy 01/2021 - 02/2005
6	Combination Drug Therapy (Combination Chemotherapy) 12/2021 - 01/2002
4	Salvage Therapy 01/2022 - 01/2002
4	Nephrectomy 01/2021 - 01/2016
4	Cystectomy 12/2020 - 04/2018
3	Aftercare (After-Treatment) 01/2021 - 01/2018
3	Adjuvant Chemotherapy 12/2020 - 03/2015
3	Hematopoietic Stem Cell Transplantation 01/2020 - 01/2002
3	Drug Tapering 01/2017 - 04/2014
3	Transplantation 01/2017 - 04/2014